Cirrhosis with increased density of the liver: Amiodarone-induced hepatotoxicity

##plugins.themes.academic_pro.article.sidebar##

Published Jun 5, 2012
Download
pdf
Vol. 90 No. 6 (2012): Issue Jun 2012

##plugins.themes.academic_pro.article.main##

Nabil Ben Chaabane
Olfa Hellara
Leila Safer
Wissem Melki
Fethia BDIOUI
Abdelfattah Zakhama
Hammouda Saffar

##plugins.themes.academic_pro.article.details##

References

  1. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM, Stohler JL. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988; 93: 54-9.
  2. Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M. Longterm efficacy and toxicity of high- and low-dose amiodarone regimens. J Clin Pharmacol 1989; 29: 418-23.
  3. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-8.
  4. Kum LC, Chan WW, Hui HH, et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. Clin Cardiol. 2006; 29:295-9.
  5. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984; 311: 167-72.
  6. Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 1984; 86: 926-6.
  7. Goldman IS, Winkler ML, Raper SE, et al. Increased hepatic density and phospholipidosis due to amiodarone. Am J Roentgenol. 1985; 144: 541-6.
  8. Kojima S, Kojima S, Ueno H, Takeya M, Ogawa H. Increased density of the liver and amiodarone-associated phospholipidosis. Cardiol Res Pract. 2009:1-3.